DCN 01
Alternative Names: DCN01Latest Information Update: 23 Dec 2019
At a glance
- Originator Deacon Biosciences Inc
- Class Antibacterials; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ophthalmic infections
Most Recent Events
- 23 Dec 2019 No development reported - Phase-II for Ophthalmic infections (Prevention) in USA (Topical)